PressReleaseCC

Latest Press Releases from Around the World

Glaucoma Drugs Market Size 2034 | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon

Glaucoma Drugs Market Size 2034 | Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon

DelveInsight’s “Glaucoma Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology and the Glaucoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Explore the intricate details of the Glaucoma Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Glaucoma Market Forecast. Click here to stay ahead in healthcare innovation @ Glaucoma Market Size

 

Key Takeaways from the Glaucoma Market Report

  • The Glaucoma diagnosed prevalent cases were further divided into open-angle glaucoma (OAG) and closed-angle glaucoma. The distribution showed that nearly 90% of glaucoma cases are of OAG type.
  • Primary Open-Angle Glaucoma (POAG) and Secondary Open-Angle Glaucoma (SOAG) are two types of Open-angle glaucoma.
  • Normal tension glaucoma (NTG) is a subtype of POAG occurring in the presence of normal IOP. As per DelveInsight’s estimates, of all POAG cases in the 7MM, 52% were of NTG type.
  • Among EU4 and the UK, Germany had the highest diagnosed prevalent population of glaucoma, with 701,946 cases, followed by France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population of glaucoma among EU4 and the UK in 2022.
  • Japan accounted for 23% of the total diagnosed prevalent cases of Glaucoma in the 7MM in 2022.
  • The leading Glaucoma Companies such as Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
  • Promising Glaucoma Pipeline Therapies such as NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/ DE-126/ ONO-9054/ STN-1012600, Catioprost/ DE-130A/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.

 

Navigate the complexities of the Glaucoma Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Glaucoma Market Forecast. Click here to get more insights @ Glaucoma Treatment Market

 

Glaucoma Epidemiology Segmentation in the 7MM

  • Total Glaucoma Prevalence Cases
  • Prevalent Cases of Glaucoma by severity
  • Glaucoma Gender-specific Prevalence Cases
  • Diagnosed Cases of Episodic and Chronic Glaucoma

 

Delve deep into the Glaucoma Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Glaucoma Market Forecast. Click here to shape the future @ Glaucoma Prevalence

 

Glaucoma Market Insights

Glaucoma is an eye disease that gradually steals vision. There are typically no early warning signs or painful symptoms of glaucoma. It develops slowly and sometimes without noticeable sight loss for many years. The damage caused by glaucoma cannot be reversed. But, treatment and regular checkups can help slow or prevent vision loss, especially if the disease is in its early stages. Glaucoma is treated by lowering the eye pressure (intraocular pressure). Depending on the situation, the options may include prescription eye drops, oral medications, laser treatment, surgery, or a combination.

 

Glaucoma Treatment Market Landscape

Management of the condition revolves around reducing intraocular pressure (IOP) through the use of current drug classes, including prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. Despite these treatments, some patients do not experience the desired improvement in their condition. They may still face optic nerve damage even when their IOP levels are within the normal range. In addition to pharmacological treatments, alternatives such as incisional surgery, laser surgery, and medications are also considered.

 

Glaucoma Drugs Uptake

  • NCX 470 is a novel NO-donating bimatoprost eye drop, which is a prostaglandin analog. The drug is currently being developed by Nicox Ophthalmics and is in Phase III of clinical development. It is being developed for the treatment of open-angle glaucoma or ocular hypertension in the US. NCX 470 is designed to release bimatoprost and NO following instillation into the eye.
  • PDP-716 is a novel, once-a-day formulation of brimonidine developed using SPARC’s TearAct technology for the treatment of glaucoma. The drug provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. The drug contains brimonidine, one of the most commonly used treatments for glaucoma and ocular hypertension.
  • STN-1012600 is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect in reducing intraocular pressure, STN-1012600 is expected to give new therapeutic options for treating glaucoma.

 

Glaucoma Market Outlook

The report’s outlook on the Glaucoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Glaucoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Glaucoma drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Glaucoma market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Major Glaucoma Companies

Several Glaucoma Companies working in the market include Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.

 

Unlock insights into the Glaucoma Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Glaucoma Market Forecast. Click here @ Glaucoma Market Drivers and Barriers

 

Scope of the Glaucoma Market Research Report

  • Coverage- 7MM
  • Glaucoma Companies- Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
  • Glaucoma Therapies- NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/ DE-126/ ONO-9054/ STN-1012600, Catioprost/ DE-130A/ STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, and others.
  • Glaucoma Market Dynamics: Glaucoma Market Drivers and Barriers
  • Glaucoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Gain a strategic edge in the Glaucoma Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Glaucoma Market Forecast. Click here to lead in advancements @ Glaucoma Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Country-wise Glaucoma Market Overview at a Glance

4. Glaucoma Market Overview by Class

5. Methodology of Glaucoma Epidemiology and Market

6. Executive Summary of Glaucoma

7. Key Events

8. Disease Background and Overview of Glaucoma

9. Epidemiology and Patient Population

10. Patient Journey

11. Glaucoma Marketed Therapies

12. Glaucoma Emerging Therapies

13. Glaucoma Market Analysis

14. Key Opinion Leaders’ Views

15. Glaucoma SWOT Analysis

16. Glaucoma Unmet needs

17. Glaucoma Market Access and Reimbursement

18. Appendix

19. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Leave a Reply

Your email address will not be published. Required fields are marked *